Prediction of NRM by MAP and clinical responses after 4 weeks of systemic therapy for GVHD. (A) Cumulative incidence of NRM for patients according to clinical response to GVHD therapy (left) and no response (right) analyzed by high (red dash) or low (blue dash) MAP. (B) Crude proportion of 6-month NRM (± standard error) for each clinical GVHD grade after 4 weeks of treatment according to response (light green box) or no response (purple box) of clinical symptoms (left), or low (blue box) or high (red box) MAP (right).